AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 45 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $92,351 | +64481.1% | 318,451 | 0.0% | 0.00% | -100.0% |
Q4 2022 | $143 | -99.9% | 318,451 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $168,000 | -48.3% | 318,451 | -50.5% | 0.00% | 0.0% |
Q2 2022 | $325,000 | -73.0% | 642,835 | +22.9% | 0.00% | -66.7% |
Q1 2022 | $1,203,000 | -39.2% | 523,142 | +25.7% | 0.00% | -50.0% |
Q4 2021 | $1,977,000 | -6.9% | 416,174 | +55.8% | 0.01% | -14.3% |
Q3 2021 | $2,123,000 | +8.2% | 267,066 | -5.3% | 0.01% | 0.0% |
Q2 2021 | $1,963,000 | +67.8% | 282,068 | +90.9% | 0.01% | +40.0% |
Q1 2021 | $1,170,000 | -7.6% | 147,790 | -8.1% | 0.01% | -16.7% |
Q4 2020 | $1,266,000 | +47.2% | 160,885 | +32.6% | 0.01% | +20.0% |
Q3 2020 | $860,000 | -72.1% | 121,344 | -63.5% | 0.01% | -75.0% |
Q2 2020 | $3,078,000 | +3040.8% | 332,731 | +2498.9% | 0.02% | +1900.0% |
Q3 2019 | $98,000 | -93.1% | 12,803 | -93.8% | 0.00% | -90.9% |
Q2 2019 | $1,423,000 | +88.0% | 207,794 | +121.0% | 0.01% | +57.1% |
Q1 2019 | $757,000 | – | 94,027 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 340,679 | $3,604,000 | 1.39% |
Nantahala Capital Management | 2,213,052 | $23,414,000 | 0.95% |
SCP Investment, LP | 156,137 | $1,652,000 | 0.82% |
SPHERA FUNDS MANAGEMENT LTD. | 509,118 | $5,386,000 | 0.74% |
DELTEC ASSET MANAGEMENT LLC | 151,781 | $1,606,000 | 0.32% |
Rock Springs Capital Management LP | 650,000 | $6,877,000 | 0.26% |
Orbimed Advisors | 1,865,524 | $19,737,000 | 0.24% |
Baker Brothers Advisors | 1,387,872 | $14,684,000 | 0.11% |
EAM Investors, LLC | 56,726 | $600,000 | 0.10% |
Stanley-Laman Group, Ltd. | 35,036 | $371,000 | 0.08% |